Human Immunoglobulin for Intravenous Injection Market

The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural lgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.

Human Immunoglobulin for Intravenous Injection Market contains market size and forecasts of Human Immunoglobulin(pH4) for Intravenous Injection in global, including the following market information:

• Global Human Immunoglobulin(pH4) for Intravenous Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Human Immunoglobulin(pH4) for Intravenous Injection Market Sales, 2017-2022, 2023-2028, (K Units)
• Global top five Human Immunoglobulin(pH4) for Intravenous Injection companies in 2021 (%)

• The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
• 1g/20ml Segment to Reach $ Million by 2028, with a % CAGR in next six years.
• The global key manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
• We surveyed the Human Immunoglobulin(pH4) for Intravenous Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Global Human Immunoglobulin(pH4) for Intravenous Injection Market Segment Percentages, by Type, 2021 (%)

• 1g/20ml
• 1.25g/25ml
• 2.5g/50ml
• 5g/100ml
• 10g/200ml

Global Human Immunoglobulin(pH4) for Intravenous Injection Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Human Immunoglobulin(pH4) for Intravenous Injection Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

The report also provides analysis of leading market participants including:

• Key companies Human Immunoglobulin(pH4) for Intravenous Injection revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Human Immunoglobulin(pH4) for Intravenous Injection revenues share in global market, 2021 (%)
• Key companies Human Immunoglobulin(pH4) for Intravenous Injection sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Human Immunoglobulin(pH4) for Intravenous Injection sales share in global market, 2021 (%)

• Boya-Bio
• Beijing Tiantan Biological Products
• Hualan Bio
• Guangdong Shuagnlin Bio-pharmacy
• Weiguang Biological
• Sinopharm
• Shanghai RAAS
• CTBB
• Nanyue Biopharming